Luxembourg-based biotechnology company USIL Therapeutics has passed the initial vendor registration assessment of the NATO Support and Procurement Agency (NSPA), marking a step towards making its treatments for acute radiation syndrome available through NATO procurement channels.
The approval confirms that the company meets the NSPA's initial registration requirements, granting it access to the agency's procurement platform and the opportunity to participate in Request for Proposal processes.
The final stage of registration is now underway and requires a Declaration of Eligibility from the relevant national authorities.
The company has not yet confirmed full registration or secured any NATO procurement contracts.
Founded last year, USIL Therapeutics is developing medical countermeasures for acute radiation syndrome, a potentially life-threatening condition caused by exposure to high doses of ionising radiation.
Its work aims to address gaps in medical preparedness for nuclear and radiological emergencies.
"For a company at our stage, reaching this point in the NATO procurement process is an important achievement and a significant opportunity," said CEO Fred Marin.
The milestone follows a period of development and institutional engagement for the company. In May, it secured a €5.2m grant from the European Commission's EU4Health programme, administered by the Health Emergency Preparedness and Response Authority (HERA), to support the development of treatments for acute radiation syndrome.
Then, in July, the company also announced a collaboration with AI and data analytics firm Ariana Pharma to develop a mechanistic AI model to support the clinical evaluation of its UT-241 candidate.
The project aims to strengthen the translational evidence base for the treatment in an indication where conventional clinical trials present significant challenges.